X4 Pharmaceuticals Inc
XFOR1.630USD
+0.030+1.87%
交易中 （美東）報價延遲15分鐘
314.52K總市值
0.02本益比TTM
關於 X4 Pharmaceuticals Inc 公司
X4 Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於發現和開發用於治療罕見疾病和治療選擇有限的疾病的新型療法，重點是治療由免疫系統功能障礙引起的疾病。其主要臨牀候選藥物是 mavorixafor，一種趨化因子受體 CXCR4 的小分子選擇性拮抗劑，正在開發爲口服、每日一次的療法。該公司已經開發了一系列趨化因子受體 CXC 受體 4 型 (CXCR4) 的小分子口服拮抗劑。該公司有兩種臨牀前候選藥物：X4P-003，一種第二代 CXCR4 拮抗劑，旨在具有比 mavorixafor 更強的特性，可能爲 CXCR4 依賴性疾病和原發性免疫缺陷提供機會，以及 X4P-002，一種具有分佈特徵和已證實能夠穿過血腦屏障的 CXCR4 拮抗劑。
公司簡介
公司代碼XFOR
公司名稱X4 Pharmaceuticals Inc
上市日期Nov 16, 2017
CEODr. Paula Ragan, Ph.D.
員工數量143
證券類型Ordinary Share
年結日Nov 16
公司地址61 North Beacon Street
城市BOSTON
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編02134
電話18575298300
網址https://www.x4pharma.com/
公司代碼XFOR
上市日期Nov 16, 2017
CEODr. Paula Ragan, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
5.56K
+36.98%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
5.34K
+23.97%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
4.72K
+46.55%
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Mr. Adam S. Mostafa
Mr. Adam S. Mostafa
Chief Financial Officer, Treasurer, Corporate Secretary
Chief Financial Officer, Treasurer, Corporate Secretary
--
--
Dr. Christophe Arbetengels, Ph.D.
Dr. Christophe Arbetengels, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Murray W. Stewart, M.D.
Dr. Murray W. Stewart, M.D.
Director
Director
--
--
Mr. Daniel Ferry
Mr. Daniel Ferry
Managing Director
Managing Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Paula Ragan, Ph.D.
Dr. Paula Ragan, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
36.25K
-67.42%
Dr. Mary Dibiase, Ph.D.
Dr. Mary Dibiase, Ph.D.
Chief Operating Officer
Chief Operating Officer
35.21K
+159.96%
Mr. Michael S. Wyzga
Mr. Michael S. Wyzga
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
5.56K
+36.98%
Mr. Mark Baldry
Mr. Mark Baldry
Chief Commercial Officer
Chief Commercial Officer
5.34K
+23.97%
Dr. Gary J. Bridger, Ph.D.
Dr. Gary J. Bridger, Ph.D.
Director
Director
4.72K
+46.55%
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月23日 週三
更新時間: 7月23日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Bain Capital Life Sciences Investors, LLC
9.52%
New Enterprise Associates (NEA)
8.43%
BlackRock Institutional Trust Company, N.A.
5.97%
The Vanguard Group, Inc.
4.54%
Acorn Capital Advisors, LLC
4.11%
Other
67.43%
持股股東
持股股東
佔比
Bain Capital Life Sciences Investors, LLC
9.52%
New Enterprise Associates (NEA)
8.43%
BlackRock Institutional Trust Company, N.A.
5.97%
The Vanguard Group, Inc.
4.54%
Acorn Capital Advisors, LLC
4.11%
Other
67.43%
股東類型
持股股東
佔比
Investment Advisor
30.62%
Venture Capital
8.46%
Hedge Fund
7.05%
Investment Advisor/Hedge Fund
5.75%
Private Equity
4.96%
Individual Investor
2.82%
Research Firm
0.91%
Bank and Trust
0.09%
Pension Fund
0.04%
Other
39.30%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
221
3.60M
60.71%
-1.69M
2025Q1
225
3.45M
58.17%
-2.00M
2024Q4
216
103.66M
60.78%
-53.08M
2024Q3
212
110.90M
65.83%
-43.36M
2024Q2
209
114.19M
68.28%
-40.11M
2024Q1
203
115.38M
69.15%
-30.64M
2023Q4
192
109.42M
65.98%
-32.86M
2023Q3
189
132.64M
89.63%
+450.20K
2023Q2
191
133.25M
115.52%
+52.30M
2023Q1
171
81.27M
73.10%
+5.35M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Bain Capital Life Sciences Investors, LLC
563.86K
9.52%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
499.56K
8.43%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
353.91K
5.97%
+11.94K
+3.49%
Mar 31, 2025
The Vanguard Group, Inc.
268.92K
4.54%
-4.45K
-1.63%
Mar 31, 2025
Acorn Capital Advisors, LLC
243.69K
4.11%
--
--
Mar 31, 2025
Kingdon Capital Management, L.L.C.
233.33K
3.94%
+68.77K
+41.79%
Mar 31, 2025
OrbiMed Advisors, LLC
225.88K
3.81%
-11.90K
-5.00%
Mar 31, 2025
UBS Financial Services, Inc.
167.91K
2.83%
+137.14K
+445.70%
Mar 31, 2025
Geode Capital Management, L.L.C.
120.66K
2.04%
+4.08K
+3.50%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
Simplify Propel Opportunities ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 2000 Growth ETF
0%
Vanguard US Momentum Factor ETF
0%
查看更多
ProShares UltraPro Russell2000
佔比0%
iShares Russell 2000 Value ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
Simplify Propel Opportunities ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Invesco NASDAQ Future Gen 200 ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%
Vanguard US Momentum Factor ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
